In our most recent projects, we have found licensees for Scioderm (now Amicus) and we assisted Akebia Therapeutics in finding a licensee for its compound for chronic kidney disease anemia, which resulted in a $100 million payment to Akebia when the agreement was signed with several hundred million due as the compound develops. In 2017, we introduced Tolero to Dainippon Sumitomo (now Sumitomo) which acquired it for $750 million dollars. In 2020, we assisted Lung Therapeutics in finding a partner (Taiho) for its lead compound and in finalizing the license terms
Cole & Associates is especially well equipped to conduct or assist in primary and secondary marketing research in Japan. We have an office located in Tokyo and, as an example of our expertise, our Associates researched, wrote, and edited the Japan PharmaCyclopedic, an encyclopedic book of knowledge containing more than 1,400 pages on 112 pharmaceutical companies and markets in Japan. While we no longer publish the PharmaCyclopedic, we continue to maintain our access and knowledge of the Japanese healthcare industry, its landscape, and its initiatives.